CELL INTELLIGENCE · 肿瘤细胞治疗研究

CAR-NK 细胞中 IL-10 的耗竭增强肿瘤微环境的重编程并改善治疗效果

Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy.

胶质母细胞瘤的代谢与翻译后脆弱性：二硫死亡、糖基化及对 CAR-T 治疗的启示

Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy.

靶向 HER2 阳性实体瘤的纳米抗体 CAR-T 细胞临床前开发与筛选

Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors.

胶质母细胞瘤的 CAR-T 细胞治疗：来自数学建模的启示

CAR-T cell therapy for glioblastoma: insight from mathematical modeling.

本研究提出了一个针对胶质母细胞瘤 CAR-T 细胞治疗的综合性建模框架，强调了给药方案和耐药动态的重要性。研究结果为优化治疗策略以改善患者预后提供了有价值的指导。

靶向 ErbB2/HER2 的 CAR-NK 细胞在重现肿瘤进展的类器官模型中清除乳腺癌细胞

ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression.

CAR-NK 细胞疗法联合免疫检查点抑制在胶质母细胞瘤中诱导 NKT 细胞应答

CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma.

该联合治疗逆转了免疫抑制性肿瘤微环境，T 细胞和 NKT 细胞浸润增加。

双靶向胶质母细胞瘤细胞的双特异性杀伤细胞衔接器靶向 EGFR 和 ErbB2（HER2）促进 NKG2D-CAR 工程化 NK 细胞的有效清除

Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D

复发性胶质母细胞瘤患者颅内注射经 HER2 靶向嵌合抗原受体工程化的 NK 细胞

Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.

颅内注射 HER2 靶向 CAR-NK 细胞在复发性 GB 患者中是可行且安全的。1 108 个 NK-92/5.28.z 细胞被确定为后续扩展队列重复局部注射 CAR-NK 细胞的最大可行剂量。

胶质母细胞瘤中的 CAR-T 细胞：当前认识与有前景的未来

Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.

AAV 介导的检查点抑制剂基因转移联合 HER2 靶向 CAR-NK 细胞作为胶质母细胞瘤的实验性治疗

AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma.